{"name":"H. Lundbeck A/S","slug":"lundbeck","ticker":"HLUYY","exchange":"OTC","domain":"lundbeck.com","description":"H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.","hq":"Copenhagen, Denmark","founded":1954,"employees":"~10,000","ceo":"Charl van Zyl","sector":"Specialty Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153.4B","metrics":{"revenue":3200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Rexulti patent cliff ($1.2B at risk)","drug":"Rexulti","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Xenazine patent cliff ($500M at risk)","drug":"Xenazine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Lu AA24530","genericName":"Lu AA24530","slug":"lu-aa24530","indication":"Treatment of schizophrenia","status":"phase_2"},{"name":"Zerdol","genericName":"SERTINDOLE","slug":"sertindole","indication":"Schizophrenia","status":"marketed"},{"name":"Adjunct brexpiprazole","genericName":"Adjunct brexpiprazole","slug":"adjunct-brexpiprazole","indication":"Adjunctive treatment of major depressive disorder in adults","status":"phase_3"},{"name":"Aripiprazole and aripiprazole once-monthly","genericName":"Aripiprazole and aripiprazole once-monthly","slug":"aripiprazole-and-aripiprazole-once-monthly","indication":"Schizophrenia","status":"phase_3"},{"name":"Lu AA21004","genericName":"Lu AA21004","slug":"lu-aa21004","indication":"Major depressive disorder","status":"phase_3"},{"name":"MK0928, gaboxadol","genericName":"MK0928, gaboxadol","slug":"mk0928-gaboxadol","indication":"Insomnia","status":"phase_3"},{"name":"Memantine (once daily)","genericName":"Memantine (once daily)","slug":"memantine-once-daily","indication":"Moderate to severe Alzheimer's disease","status":"marketed"},{"name":"Memantine (twice daily)","genericName":"Memantine (twice daily)","slug":"memantine-twice-daily","indication":"Moderate to severe Alzheimer's disease","status":"marketed"},{"name":"Paliperidone and paliperidone palmitate","genericName":"Paliperidone and paliperidone palmitate","slug":"paliperidone-and-paliperidone-palmitate","indication":"Schizophrenia","status":"phase_3"},{"name":"Vortioxetine (Lu AA21004)","genericName":"Vortioxetine (Lu AA21004)","slug":"vortioxetine-lu-aa21004","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ALD1910","genericName":"ALD1910","slug":"ald1910","indication":"Other","status":"phase_1"},{"name":"Azilect®","genericName":"Azilect®","slug":"azilect","indication":"Other","status":"marketed"},{"name":"Droxidopa capsules","genericName":"Droxidopa capsules","slug":"droxidopa-capsules","indication":"Other","status":"marketed"},{"name":"Lu AG09222","genericName":"Lu AG09222","slug":"lu-ag09222","indication":"Other","status":"phase_2"},{"name":"ldalopirdine 120 mg","genericName":"ldalopirdine 120 mg","slug":"ldalopirdine-120-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ALD1910","genericName":"ALD1910","slug":"ald1910","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Lu AA24530","genericName":"Lu AA24530","slug":"lu-aa24530","phase":"phase_2","mechanism":"Selective 5-HT6 receptor antagonist","indications":["Treatment of schizophrenia"],"catalyst":""},{"name":"Zerdol","genericName":"SERTINDOLE","slug":"sertindole","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2C","indications":["Schizophrenia"],"catalyst":""},{"name":"Adjunct brexpiprazole","genericName":"Adjunct brexpiprazole","slug":"adjunct-brexpiprazole","phase":"phase_3","mechanism":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy.","indications":["Adjunctive treatment of major depressive disorder in adults"],"catalyst":""},{"name":"Aripiprazole and aripiprazole once-monthly","genericName":"Aripiprazole and aripiprazole once-monthly","slug":"aripiprazole-and-aripiprazole-once-monthly","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Irritability associated with autism spectrum disorder"],"catalyst":""},{"name":"Azilect®","genericName":"Azilect®","slug":"azilect","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Droxidopa capsules","genericName":"Droxidopa capsules","slug":"droxidopa-capsules","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lu AA21004","genericName":"Lu AA21004","slug":"lu-aa21004","phase":"phase_3","mechanism":"Lu AA21004 is a multimodal antidepressant that acts as a serotonin reuptake inhibitor, serotonin 5-HT1A receptor agonist, and serotonin 5-HT7 receptor antagonist.","indications":["Major depressive disorder"],"catalyst":""},{"name":"Lu AG09222","genericName":"Lu AG09222","slug":"lu-ag09222","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0928, gaboxadol","genericName":"MK0928, gaboxadol","slug":"mk0928-gaboxadol","phase":"phase_3","mechanism":"Gaboxadol is a selective GABA-A receptor agonist that enhances inhibitory neurotransmission in the central nervous system.","indications":["Insomnia","Anxiety disorders"],"catalyst":""},{"name":"Memantine (once daily)","genericName":"Memantine (once daily)","slug":"memantine-once-daily","phase":"marketed","mechanism":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity.","indications":["Moderate to severe Alzheimer's disease"],"catalyst":""},{"name":"Memantine (twice daily)","genericName":"Memantine (twice daily)","slug":"memantine-twice-daily","phase":"marketed","mechanism":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain.","indications":["Moderate to severe Alzheimer's disease","Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors)"],"catalyst":""},{"name":"Paliperidone and paliperidone palmitate","genericName":"Paliperidone and paliperidone palmitate","slug":"paliperidone-and-paliperidone-palmitate","phase":"phase_3","mechanism":"Paliperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms.","indications":["Schizophrenia","Schizoaffective disorder","Bipolar I disorder (acute mania and maintenance)"],"catalyst":""},{"name":"Vortioxetine (Lu AA21004)","genericName":"Vortioxetine (Lu AA21004)","slug":"vortioxetine-lu-aa21004","phase":"phase_3","mechanism":"Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"ldalopirdine 120 mg","genericName":"ldalopirdine 120 mg","slug":"ldalopirdine-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Lundbeck Reports Q4 2023 Earnings","summary":"H. Lundbeck A/S reported its Q4 2023 earnings, with revenue of $1.23 billion and a net income of $143 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Lundbeck Partners with Biogen to Develop New Psychiatric Treatments","summary":"H. Lundbeck A/S has partnered with Biogen to develop new treatments for psychiatric disorders, including major depressive disorder and schizophrenia.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"Lundbeck Receives FDA Approval for Rexulti in Major Depressive Disorder","summary":"H. Lundbeck A/S has received FDA approval for Rexulti (brexpiprazole) in the treatment of major depressive disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQaDFHQzRBb19DNVVaSV9rOGo3WWx4bDdjaVJESmdJSzVkcXktZFc4SVlUUEM0Vnhta3gyajdUYk9ZLUd4VzdoRGNyR0oxWXgxMHBSRTQ5bTNCdUJwT1pwN0RHTURSYW04MlBpRlFGaHNkZDZNMnlaN0stY0phTTJzTG4xaENhN0NsTkthT0VUdFpDSVR6cW5mLWxxbERvczNDSFB6Z1UwR0Z2OEdSemt4SHJzdUlTeWxmcTJuSm55cmZLQTBva05yVS1Xb0N0SXF2dFVhTjBoMnB0endrendpNjJVX0c4QW54SS11UVR1eTdWX09ZdnpJOE9OWnBSSC1oX2xRQjJnVHBJZVdULXBfMEZkN2g0NFRNVnhOb2JmajEwZjZZZkYxc0gtUmtWVEVw?oc=5","date":"2021-10-13","type":"regulatory","source":"Business Wire","summary":"Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents - Business Wire","headline":"Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-09-16","type":"deal","source":"globenewswire.com","summary":"Lundbeck to acquire Alder BioPharmaceuticals – a company - globenewswire.com","headline":"Lundbeck to acquire Alder BioPharmaceuticals – a company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxNVW1HNEhzUW0xaGxxaTg4NGpobDl4RFpzZVB0eW05WUdUZHcwNzFFalBQRndkcG4yVERkOWZ3U3QwaHZ0VDNfa3hVeVhEV2lUOFJSRXRpWEd3QXExVDc1cURqbFNqWkhsX0ZvbXItRGpLTXFUN3d4dVQxNk1IbDNGLU9QM3NMNDkwQVBPeHZmQlVJYmlQbDF6RVcwb2F5M280YTY3Nl94a2kyLUlnVUE0RjFzNnEtSDNGczc2X2Exb25ZU0VJc3hENFBwNG9wS1l0dU5yMDZkT2dKLUNEM0FJUVlLRy1CWkZ1YWVEd3hobWloTVJqRlJqTU52enRuTGk1eV81a1lKeTVZQThYdUFCOS1XMnlrUndxc1F1eXlTRF9QUGFUMElFaGwyb0xaRTlxdXk4MXdEWkpuTXp5?oc=5","date":"2019-05-06","type":"deal","source":"globenewswire.com","summary":"Lundbeck to acquire Abide Therapeutics, adding a unique - globenewswire.com","headline":"Lundbeck to acquire Abide Therapeutics, adding a unique","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-05-02","type":"regulatory","source":"globenewswire.com","summary":"FDA updates Trintellix® (vortioxetine) label to include - globenewswire.com","headline":"FDA updates Trintellix® (vortioxetine) label to include","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxNX09qQXB1VmE4NHlnd3h0a0hCc2JocGJpV2pSaXViNnJjUmZ2eW5ZSmpOWkozdlNzOGFCc2lnVEF5aURBSmVPcHJoZkNNVy1RaWd2a2hZTHlLRGMwTS11STlIMnlFeGp3Ql84VXNZYWN2WHNPd2lnRGtQZ0FXZjhEN0k2RFhhT3RoUkZtNjRDVFkxRFlxZmVPNm15NEptSDA2OV83RS1kOWNmUHF6NlZnQVVJWHFtQ09wWGhLdG90bFBEV19oeTJEanJGRi1UWEwweFEzNWoxS0dVUUJ4dFNlWGliUmVzNnoxLWFkdEdqa09VRVNWMFJtSTJsV3Q3cnlad2lXdExxNG5UcU5zMUhmNm9rMU1TeEVOWmhkVU9jVkM3Ri1MZWRmTTBsRENNSjZrNFNRanJUa0xFZzN6dWRENnpLN096UVZ2aTNYZm15Ml8zaXI0SEMxV25XWU4?oc=5","date":"2018-03-16","type":"deal","source":"globenewswire.com","summary":"Lundbeck to acquire Prexton Therapeutics adding foliglurax - globenewswire.com","headline":"Lundbeck to acquire Prexton Therapeutics adding foliglurax","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPTk96c0podzZ0WHpIMHBhNm9xRUlmcFF5aVhPVGhCUndkTnRFSndpUENfcmg2RXhlX1U3MmdHY0lKUDRwXzk1MjRIRi1ORWx1OVVnXzZMb0NrTkwyLU1OQm85Qm4tTFhtcU9neW95ekthaWlqcjU2Z1F5MXBWMHVCUUZERXlkanRHX1JtYlZNVDNQUkMxbFhub09jWFltSmF5bTBrUGN3eVBtb0gwbnEzdllSQkdacEgweHc0bmZyUnA1emJuZndEN0lFZw?oc=5","date":"2018-01-08","type":"pipeline","source":"VUMC News","summary":"Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment - VUMC News","headline":"Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZlh0d0dyUzJvS1F1dHp2amJQWmszNDV0THVNOHB6RkgtNDJMVVpDU3pTLUdON1FrcFNLdjRoU0FqRXNaelladW52UFZfd3o2RjlYVlh4amU1SGQxUERKQVcwODJmZDc0TWswYUYyUkY1VTBIYXh4MjA3QXg5eFZtX2VFakw5N3l6?oc=5","date":"2017-12-12","type":"regulatory","source":"Yahoo Finance","summary":"Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog - Yahoo Finance","headline":"Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQXzhfODhZcTFsUml1eDllRnpfNkxzbWpOQmVKcDNWQ3pJdm1MUmpDZHVlS0dRNmY1WDA2SVc2WXREc1FZQkxoUjUzTUdMcHRlM0dGNFBoWUxLam9CZm5SYjFKMTZ2SG52UnhUWmZtMzcza1QyS09pX2Q1OEdNTVN1aVdXelRpVnhicUJSMGE1QmpsX1o3ZlNaelU4UVZrZ1p6?oc=5","date":"2017-08-02","type":"trial","source":"MultiVu","summary":"23andMe Begins Enrollment for First-of-its-Kind Study on Major Depressive and Bipolar Disorders - MultiVu","headline":"23andMe Begins Enrollment for First-of-its-Kind Study on Major Depressive and Bipolar Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPOTVlSHdhRWotakhTRlE0Q3ZFdjB6dHZRcVNwRFd5dkZESXFjWHF2VWk0ZWh3NF92bWhfNElQemtUN1VpSlpDd1g1YllRdTh6YnN1Ny1iREdOR2dNcTV4OE5iZVE0TnpVaElWOTBUR25KWm1IWDdtNmZoYnVDMzNOUUNVSEF0UHJpeWlBTGgxWDNMTVFkQnpQR2xRN1c3emxm?oc=5","date":"2015-04-16","type":"pipeline","source":"Globes - Israel Business News","summary":"Former Teva CEO Jeremy Levin heads US start-up - Globes - Israel Business News","headline":"Former Teva CEO Jeremy Levin heads US start-up - Globes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQcjR1TEhQWkdZU3htbWlJMndlOExUNUctYkRBUEUxY2kzTF9tQ3hQV1BfLW0xYWZMR291bml0Mmg0UGJ3QmF0YzAyaWdaNFBFemlwS1R3LV9wMmdFNnlSTjZoaUV4RVdWMnJZaXVPRG1fcUNDV3RoQmxFYjVhekJxOGpzQklkbzlDbTNwTWRIYjNVV0wyWXdGYVBWcXgzbjJRRkdCMFNyTGhZaGplaW5HeGkzVnUwN1o5My1OeElnc1RoVk1aTlZ4eHR4cjFwWUtKOS1xTzBPX25SaEpoc3NHT2hUQ0VZMkFpZW5VeS0wU2lvejJCek5NZXVkRkZNR3V6NXh6ZA?oc=5","date":"2014-01-23","type":"pipeline","source":"BioSpace","summary":"Takeda Pharmaceuticals And Lundbeck Inc. Announce Brintellix® (Vortioxetine) For The Treatment Of Major Depressive Disorder In Adults Is Now Available In Pharmacies - BioSpace","headline":"Takeda Pharmaceuticals And Lundbeck Inc. Announce Brintellix® (Vortioxetine) For The Treatment Of Major Depressive Disor","sentiment":"neutral"}],"patents":[{"drugName":"Rexulti","drugSlug":"brexpiprazole","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Xenazine","drugSlug":"tetrabenazine","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":500000000}],"drugCount":15,"phaseCounts":{"phase_1":2,"phase_2":2,"marketed":5,"phase_3":6},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","Pfizer","Eli Lilly and Company"],"therapeuticFocus":["Psychiatric disorders","Neurological disorders"],"financials":null,"yahoo":null}